Survival Outcomes of Uterine Cervical Malignancies in Chinese Population

Uterine Cervical Neoplasms Clinical Trial

Official title:

Survival Outcomes of Uterine Cervical Malignancies in Chinese Population

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03291236
• Other study ID #: SOCM-1
• Status: Recruiting
• Phase: N/A
• First received: September 20, 2017
• Last updated: February 7, 2018
• Start date: January 1, 2017
• Est. completion date: January 1, 2023

Study information

• Verified date: February 2018
• Source: Peking Union Medical College Hospital
• Contact: Lei Li, MD
• Phone: 13911988831
• Email: lileigh[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to determine survival outcomes (overall survival and progression-free survival) of primary malignancies of uterine cervix in China and relevant risk factors in a prospective cohort study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5000
• Est. completion date: January 1, 2023
• Est. primary completion date: January 1, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Primary malignancies of uterine cervix.

Exclusion Criteria:

• Secondary malignancies of uternie cervix.

Related Conditions & MeSH terms

• Survival
• Uterine Cervical Neoplasms

Intervention

Other:
• Follow-up for death and recurrence of patients
All patients are follow-up to determine specific date of diagnosis, recurrence and death.

Locations

Country	Name	City	State
China	Lei Li	Beijing	China/Beiing

Sponsors (1)

Lead Sponsor	Collaborator
Lei Li

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	Duration from diagnosis to recurrence	5 years
Primary	Progression-free survival	Duration from last treatment after remission to recurrence	5 years